This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cardiac amyloidosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Although the heart may be involved in all forms of amyloidosis, cardiac amylodosis is most commonly a result of immunocyte disease (and resultant AL fibril deposition). Clinical cardiac abnormality is also associated with deposition of AA fibrils in familial Mediterrranean fever.

It is often an incidental post-mortem finding in an elderly patient (>50% of those over 70 yrs have cardiac amyloid). Deposits are usually widely spaced but when they occur subendocardially there is a risk of conducting tissue damage and arrhythmias.

Cardiac amyloidosis is a cause of restrictive cardiomyopathy.

Click here for ECGs and further information

Cardiovascular involvement of amyloidosis is present in 90% of cases, which is frequently associated with the primary form of the disease (AL amyloidosis).

  • clinical manifestations are represented by heart failure due to restrictive myocardiopathy and electrical impulse conduction abnormalities, which are clinically remarkable in up to 50% of the cases

The prognosis of patients with systemic amyloidosis (AL amyloidosis) is directly associated with the presence of cardiac involvement, such that survival does not usually exceed 4 months after the onset of heart failure signs and symptoms (1)

Transthyretin amyloid (aTTR) cardiomyopathy

  • results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally involved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium
    • can be inherited as an autosomal dominant trait caused by pathogenic variants in the transthyretin gene TTR (ATTRv)
    • or
    • by the deposition of ATTRwt (wild-type transthyretin protein), previously called senile cardiac amyloidosis
  • survival is much better for TTRamyloid compared to AL amyloidosis
  • targets for disease-modifying therapies in cardiac amyloidosis include TTR silencing, TTR stabilization, and TTR disruption

Reference:

  • Morais GCP et al. Cardiac amyloidosis: a challenging diagnosis.Autops Case Rep. 2014 Oct-Dec; 4(4): 9-17
  • Cavusoglu Y et al. Cardiac amyloidosis: Recent advances in the diagnosis and therapy.Turk Kardiyol Dern Ars. 2019; 47(2): 1-34 | DOI: 10.5543/tkda.2019.28035
  • Kittleson MM et al. Cardiac Amyloidosis: Evolving Diagnosis and Management - A Scientific Statement From the American Heart Association.Circulation. 2020;142:e7-e22. DOI: 10.1161/CIR.0000000000000792

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.